Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
ORASURE TECHNOLOGIES INC (OSUR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 08/02/2023 |
8-K/A
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/20/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ORASURE TECHNOLOGIES, INC. STOCK AWARD PLAN ARTICLE 1 ESTABLISHMENT AND PURPOSE Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29, 2000, in connection with the merger of Epitope, Inc. with and into OraSure Technologies, Inc., the name of the Plan was changed to the OraSure Technologies, Inc. 2000 Stock Award Plan and the Plan was adopted as a stock award plan of OraSure Technologies, Inc. The Plan was amended and restated, subject to shareholder approval, effective May 16, 2006. The Plan was amended further, subject to shareholder approval, effective May 13, 2008. The Plan again was amended..." |
|
| 05/12/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 05/10/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 03/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year InteliSwab® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production InteliSwab® gross margins improve sequentially by over 2,000 basis points GAAP gross margin of 34.4%, a decrease of 200 basis points sequentially; non-GAAP gross margins improve 250 basis points sequentially to 40.1% despite headwinds Q2 GAAP EPS of and non-GAAP EPS of Company expects to generate positive cash flow in the 4Q22 Announces strategic transformation, including appointment of new Chief Financial Officer and changes in the Board of Directors to occur in November Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, August 9, 2022 -- OraSure Technologies, Inc. , a l...",
"FINANCIAL METRIC 2Q22 RESULTS 1Q22 RESULTS 2Q21 RESULTS SEQUENTIAL GROWTH RATE YEAR-OVER-YEAR GROWTH RATE" |
|
| 07/15/2022 |
8-K/A
| Quarterly results |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/18/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue InteliSwab® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production Non-COVID molecular kits increase 42% year-over-year demonstrating continued strong growth Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, May 10, 2022 -- OraSure Technologies, Inc. , a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2022. “We made significant progress in the quarter scaling InteliSwab® production and improving the efficiency of our manufacturing process as we...",
"FINANCIAL METRIC 1Q22 RESULTS 1Q21 RESULTS YEAR-OVER-YEAR GROWTH RATE" |
|
| 03/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up Total 2021 revenue of $233.7 million, up 36% year-over year InteliSwab® receives emergency use authorization expansion and demonstrates accurate detection of Omicron variant InteliSwab® revenue of $14.7 million in Q4, up 92% sequentially Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, Feb. 23, 2022 -- OraSure Technologies, Inc. , a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended December 31, 2021 and fiscal year 2021. “We are pleased to have delivered record revenue from both our Diagnostics and Molecular...",
"FINANCIAL METRIC 4Q21/FY21 RESULTS 4Q20/FY20 RESULTS YEAR-OVER-YEAR GROWTH RATE" |
|
| 01/10/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"TRANSITION AGREEMENT This Transition Agreement is made on January 2, 2022 by and between Stephen S. Tang, Ph.D. and OraSure Technologies, Inc. : RECITALS WHEREAS, Executive is presently employed by the Company as its President and Chief Executive Officer, and also serves as a member of the Company’s Board of Directors ; and WHEREAS, Executive and the Company are currently parties to an Employment Agreement, dated as of January 3, 2018 ; and WHEREAS, Executive’s employment with the Company will soon cease; and WHEREAS, Executive and the Company have entered into this Agreement to set forth the terms and conditions of Executive’s remaining period of employment and Executive’s entitlements in connection with the cessation of his employment. NOW THEREFORE, in consideration of the mutual promis..." |
|
| 11/10/2021 |
8-K
| Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhib... |
| 11/09/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"RETIREMENT AGREEMENT This Retirement Agreement is made as of November 9, 2021, by and between Jack E. Jerrett and OraSure Technologies, Inc. : RECITALS WHEREAS, Executive has been employed by the Company as its Senior Vice President, General Counsel and Chief Compliance Officer; and WHEREAS, Executive and the Company are currently parties to an Employment Agreement, dated as of July 4, 2004, as amended ; and WHEREAS, Executive will retire from the Company on December 31, 2021 ; and WHEREAS, in consideration of Executive’s service to the Company and his retirement, Executive and the Company have entered into this Agreement to set forth the terms and conditions of Executive’s employment between the date hereof and the Retirement Date and the amicable termination of Executive’s employment as ...",
"OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary BETHLEHEM, PA., Nov. 9, 2021 – OraSure Technologies, Inc. , a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company’s Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack’s roles as the new General Counsel, Chief Compliance Officer and Secretary. “J..." |
|
| 11/08/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"OraSure Technologies Appoints Two New Members to the Board of Directors New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience BETHLEHEM, PA., November 8, 2021 – OraSure Technologies, Inc. , a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today the appointment Nancy J. Gagliano, M.D. and Anne C. Whitaker to the Company’s Board of Directors, effective November 8, 2021. Dr. Gagliano was a practicing physician in internal medicine, has extensive retail pharmacy leadership experience, and was one of the leaders of the RADx Tech, Rapid Acceleration of Diagnostics program for the National Institute of Health to bring new diagnostic techn..." |
|
| 11/03/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22  Third quarter revenue of $53.9 million grew 12% year-over-year; excluding COVID-19 product revenues, revenues for the quarter grew 37% from the prior year, demonstrating strong growth  OraSure signs three major U.S. government contracts providing $205 million in government InteliSwab™ procurement, $109 million for InteliSwab™ manufacturing capacity build out, and $13.6 million to pursue full FDA 510 clearance and CLIA waiver for InteliSwab™  Company increases financial guidance range for fiscal year 2021 and is now expecting revenues of $230-$233 million  Management to Host Analyst/Investo...",
"OraSure Technologies, Inc. Third Quarter 2021 Analyst-Investor Conference Call Prepared Remarks of Dr. Stephen S. Tang and Scott Gleason Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies third quarter 2021 financial results conference call and simultaneous webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question and answer period. If you would like to ask a question during this time, simply press “star” then the number 1 on your telephone keypad. If you would like to withdraw your question, press the # key. To allow time ...",
"FINANCIAL METRIC 3Q21 RESULTS 3Q20 RESULTS YEAR-OVER-YEAR GROWTH RATE 3Q21" |
|
| 10/04/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 09/23/2021 |
8-K
| Quarterly results |
| 09/20/2021 |
8-K
| Quarterly results |
| 09/08/2021 |
8-K
| Quarterly results |
| 09/02/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/03/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business  Excluding COVID-19 product revenues, revenues for the second quarter grew 122% YoY and 48% sequentially as the Company’s core business began to return to pre-pandemic revenue levels  Company received three Emergency Use Authorizations from the U.S. Food and Drug Administration for its InteliSwab™ COVID-19 Rapid Tests for Non-Prescription , Professional Point-of-Care and Prescription Home Use Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, PA, August 3, 2021 -- OraSure Technologies, Inc. , a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced i...",
"OraSure Technologies, Inc. Second Quarter 2021 Analyst-Investor Conference Call Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies second quarter 2021 financial results conference call and simultaneous webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question and answer period. If you would like to ask a question during this time, simply press “star” then the number 1 on your telephone keypad. If you would like to withdraw your question, press the # key. To allow time...",
"FINANCIAL METRIC 2Q21 RESULTS 2Q20 RESULTS GROWTH RATE 2Q21" |
|
| 05/26/2021 |
8-K
| Quarterly results |
|
|
|